Skip to content
CABA·Nasdaq·US

Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on developing targeted cell therapies for autoimmune diseases. Its lead program is rese-cel, an investigational CD19 CAR T cell therapy being advanced through clinical trials across several autoimmune indications.

Thematic Position

CABA

Relationship Groups

Licensing1
Competitors10

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

6 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

government march-in rightsdomestic manufacturing requirement
Bayh-Dole Act gives U.S. government march-in rights over government-funded inventions
SEC 10-QMay 14, 2026

The full regulatory passage is part of the Pro plan.

27 more · Regulatory and geopolitical insights are part of the Pro plan.